These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8757568)

  • 1. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia.
    Mak RH
    J Pediatr; 1996 Jul; 129(1):97-104. PubMed ID: 8757568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of erythropoietin in patients on peritoneal dialysis.
    Mak RH
    Pediatr Nephrol; 1998 Oct; 12(8):660-5. PubMed ID: 9811391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia.
    Mak RH
    Am J Physiol; 1996 May; 270(5 Pt 2):F839-44. PubMed ID: 8928846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia.
    Mak RH
    Kidney Int; 1998 May; 53(5):1353-7. PubMed ID: 9573552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients.
    Riedel E; Hampl H; Scigalla P; Nündel M; Kessel M
    Kidney Int Suppl; 1989 Nov; 27():S216-21. PubMed ID: 2636662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin, branched-chain amino acids, and growth failure in uremia.
    Mak RH
    Pediatr Nephrol; 1998 Oct; 12(8):637-42. PubMed ID: 9811385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients.
    Biolo G; Guarnieri G; Barazzoni R; Panzetta G
    Clin Exp Med; 2011 Sep; 11(3):181-7. PubMed ID: 21076998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
    Ifudu O; Dawood M; Friedman EA
    Nephron; 1997; 77(3):315-8. PubMed ID: 9375826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nutritional/metabolic and hormonal effects of 8 weeks of continuous ambulatory peritoneal dialysis with a 1% amino acid solution.
    Arfeen S; Goodship TH; Kirkwood A; Ward MK
    Clin Nephrol; 1990 Apr; 33(4):192-99. PubMed ID: 2190721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized prospective comparison between erythropoietin and androgens in CAPD patients.
    Navarro JF; Mora C; Macía M; García J
    Kidney Int; 2002 Apr; 61(4):1537-44. PubMed ID: 11918762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
    Tarng DC; Huang TP; Doong TI
    Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of free fatty acids on blood amino acid levels in human.
    Ferrannini E; Barrett EJ; Bevilacqua S; Jacob R; Walesky M; Sherwin RS; DeFronzo RA
    Am J Physiol; 1986 Jun; 250(6 Pt 1):E686-94. PubMed ID: 3521315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of metabolic acidosis on branched-chain amino acids in uremia.
    Mak RH
    Pediatr Nephrol; 1999 May; 13(4):319-22. PubMed ID: 10454782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of erythropoietin on glucose tolerance in hemodialysis patients.
    Chagnac A; Weinstein T; Zevin D; Korzets A; Hirsh J; Gafter U; Levi J
    Clin Nephrol; 1994 Dec; 42(6):398-400. PubMed ID: 7882604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.